This site is intended for UK healthcare professionals

 
This promotional video has been developed, organised, and funded by Novartis Pharmaceuticals. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast. Editorial support for this video has been provided by OmniaMed Communications.

Click here to access ENTRESTO® (sacubitril/valsartan) prescribing information.
ENTRESTO® (sacubitril/valsartan) is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction1
Adverse events reporting information can be found at the bottom of the page.
novartis-logo-transparent
03:43

Heart Failure Foundation Course: Diagnosis and investigation of patients with heart failure

1 August 2024

Sponsored

03:43
In this summary video, Maggie Simpson (Cardiology Advanced Nurse Practitioner, NHS Greater Glasgow & Clyde) discusses the route to diagnosing heart failure in the UK, including recognising the signs and symptoms, staging criteria and the NICE heart failure diagnosis algorithm.

To watch the full on-demand video and other videos in this series click here (this will direct to Novartis promotional content).


Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email [email protected] or call 01276 698370. 

References

  1. ENTRESTO® (sacubitril/valsartan) Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/medicine/3124
 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

BJC TV

To continue, please confirm that you are a UK healthcare professional.